Related Experiment Video

Updated: Sep 21, 2026

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

Adrenomedullin and heart failure

Miriam T Rademaker1, Vicky A Cameron, Christopher J Charles

  • 1The Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand. miriam.rademaker@chmeds.ac.nz

Regulatory Peptides
|April 2, 2003
PubMed

Insights

Adrenomedullin (AM) is elevated in heart failure, predicting outcomes and identifying patients who benefit from carvedilol. AM administration improves heart function and renal function in heart failure.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Nephrology

Background:

  • Adrenomedullin (AM) is implicated in heart failure pathophysiology.
  • Elevated circulating AM correlates with cardiovascular disease severity and prognosticates adverse outcomes.
  • Raised AM levels in heart failure patients predict benefit from carvedilol therapy.

Purpose of the Study:

  • To investigate the role and therapeutic potential of adrenomedullin (AM) in heart failure.
  • To assess AM's prognostic value and its interaction with existing heart failure therapies.

Main Methods:

  • Analysis of circulating AM concentrations in cardiovascular disease patients.
  • Administration of AM in experimental and human heart failure models.
  • Evaluation of hemodynamic, renal, and hormonal responses to AM therapy.
  • Assessment of combined therapy effects (AM with ACE inhibitors and natriuretic peptides).

Main Results:

  • Elevated plasma AM levels in heart failure correlate with disease severity and predict adverse outcomes.
  • AM administration in heart failure reduces arterial and filling pressures, improving cardiac output.
  • AM inhibits aldosterone, sustains renal glomerular filtration, and promotes sodium excretion.
  • Combined AM therapy with ACE inhibitors and natriuretic peptides yields superior hemodynamic and renal benefits.

Conclusions:

  • The adrenomedullin system is a promising therapeutic target for cardiovascular diseases, particularly heart failure.
  • AM has significant prognostic and therapeutic implications in managing heart failure patients.
  • Targeting the AM system offers a novel strategy for improving cardiovascular and renal function in heart failure.

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...